Scilex Holding Company (SCLX)
NASDAQ: SCLX · Real-Time Price · USD
0.448
+0.007 (1.64%)
At close: Dec 20, 2024, 4:00 PM
0.449
+0.002 (0.34%)
After-hours: Dec 20, 2024, 6:41 PM EST
Scilex Holding Company Employees
Scilex Holding Company had 105 employees as of December 31, 2023. The number of employees increased by 15 or 16.67% compared to the previous year.
Employees
105
Change (1Y)
15
Growth (1Y)
16.67%
Revenue / Employee
$484,124
Profits / Employee
-$1,633,648
Market Cap
58.95M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 105 | 15 | 16.67% |
| Dec 31, 2022 | 90 | 14 | 18.42% |
| Dec 31, 2021 | 76 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Apyx Medical | 252 |
| Atara Biotherapeutics | 225 |
| Repare Therapeutics | 179 |
| Vor Biopharma | 168 |
| BioAtla | 65 |
| Kronos Bio | 63 |
| Oncolytics Biotech | 29 |
| Milestone Scientific | 17 |
SCLX News
- 8 days ago - Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering - GlobeNewsWire
- 9 days ago - Scilex Holding Company Announces $17 Million Registered Direct Offering - GlobeNewsWire
- 10 days ago - Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - GlobeNewsWire
- 10 days ago - Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor - GlobeNewsWire
- 4 weeks ago - Scilex Holding Company Announces Receipt of Notice from Nasdaq - GlobeNewsWire
- 6 weeks ago - Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali - GlobeNewsWire
- 7 weeks ago - Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms - GlobeNewsWire
- 7 weeks ago - Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock - GlobeNewsWire